AbbVie’s upadacitinib succeeds in phase 3 rheumatoid arthritis trial
The trail demonstrated that upadacitinib achieved the primary endpoints of ACR20a and clinical remission remissionb against placebo placebo, as well as achieved all ranked secondary endpoints against either